The lab was opened earlier this year as the company's central genomics lab in North America, offering various genomic services such as DNA sequencing.
The certification ensures that the biobank has the authority to handle and test human samples for the Cancer MoonShot 2020 initiative.
The certification enables the company to offer its flow cytometry-based myeloid-derived suppressor cell assay for cancer patients.
The point-of-care test detects and distinguishes influenza A and B as well as respiratory syncytial virus in about 20 minutes.
The certification enables the company's lab in Grenoble to receive patient specimens from the US for testing with its ImmuneTracker Dx cancer immunotherapy assay.
The molecular diagnostics arm of Patrick Soon-Shiong's healthcare empire performs sequencing and proteomic analysis for the GPS Cancer test.
Regulators have proposed banning Theranos CEO from owning or operating any lab for two years, the Wall Street Journal reports.
The firm aims to establish a CLIA-certified laboratory within the facility and provide whole-genome sequencing services for human, plant, and animal samples.
The state of California has given the lab permission to start offering its QClamp test to screen for tumor oncogenic driver and resistance mutations in tumor DNA.
It is also the first such lab in China to be licensed by the State of California, allowing it to process samples from the state.
In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.
Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.
The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.
Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.